Search Results

There are 2144 results for: content related to: Piecing together the puzzle of progression and mortality in Parkinson's disease

  1. Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules

    The Journal of Clinical Pharmacology

    Volume 47, Issue 10, October 2007, Pages: 1256–1267, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270007304779

  2. Monoamine oxidase B inhibitors for early Parkinson's disease

    Intervention Review

    The Cochrane Library

    Kristian Turnbull, Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD004898.pub2

  3. Selegiline for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline Birks and Leon Flicker

    Published Online : 20 JAN 2003, DOI: 10.1002/14651858.CD000442

  4. You have free access to this content
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline

    British Journal of Pharmacology

    Volume 143, Issue 3, October 2004, Pages: 371–378, Zaid A Abassi, Ofer Binah and Moussa B H Youdim

    Article first published online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705962

  5. Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 146–158, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270006296151

  6. You have free access to this content
    Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids

    British Journal of Clinical Pharmacology

    Volume 47, Issue 3, March 1999, Pages: 249–254, Kari Laine, Markku Anttila, Antti Helminen, Hari Karnani and Risto Huupponen

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00891.x

  7. You have free access to this content
    Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

    British Journal of Pharmacology

    Volume 149, Issue 6, November 2006, Pages: 647–656, J P M Finberg, A Gross, O Bar-Am, R Friedman, Y Loboda and M B H Youdim

    Article first published online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706908

  8. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

    Movement Disorders

    Volume 19, Issue 4, April 2004, Pages: 426–432, Cheryl H. Waters, Kapil D. Sethi, Robert A. Hauser, Eric Molho and John M. Bertoni

    Article first published online : 10 FEB 2004, DOI: 10.1002/mds.20036

  9. You have free access to this content
    Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo

    British Journal of Pharmacology

    Volume 126, Issue 4, February 1999, Pages: 997–1002, Itschak Lamensdorf, Shai Porat, Rabi Simantov and John P M Finberg

    Article first published online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0702389

  10. You have free access to this content
    Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease

    British Journal of Clinical Pharmacology

    Volume 74, Issue 2, August 2012, Pages: 284–295, Thuy C. Vu, John G. Nutt and Nicholas H. G. Holford

    Article first published online : 10 JUL 2012, DOI: 10.1111/j.1365-2125.2012.04208.x

  11. Changes in vascular alpha1- and alpha2-adrenoceptor responsiveness by selegiline treatment

    Fundamental & Clinical Pharmacology

    Volume 15, Issue 4, August 2001, Pages: 239–245, M. Pelat, P. Verwaerde, M. A. Tran, M. Berlan, J. M. Senard and J. L. Montastruc

    Article first published online : 7 JUL 2008, DOI: 10.1046/j.1472-8206.2001.00036.x

  12. You have free access to this content
    Neuroprotective actions of selegiline

    Journal of Neuroscience Research

    Volume 67, Issue 3, 1 February 2002, Pages: 285–289, M. Ebadi, S. Sharma, S. Shavali and H. El Refaey

    Article first published online : 7 JAN 2002, DOI: 10.1002/jnr.10148

  13. You have free access to this content
    Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

    Journal of Neurochemistry

    Volume 105, Issue 5, June 2008, Pages: 1970–1978, Wen Zhu, Wenjie Xie, Tianhong Pan, Joseph Jankovic, Jun Li, Moussa B. H. Youdim and Weidong Le

    Article first published online : 8 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05330.x

  14. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Article first published online : 21 OCT 2011, DOI: 10.1002/mds.23829

  15. Effects of combined treatment with clorgyline and selegiline on extracellular noradrenaline and serotonin levels

    Acta Neuropsychiatrica

    Volume 24, Issue 6, December 2012, Pages: 369–373, Yuji Kitaichi, Takeshi Inoue, Shin Nakagawa, Shuken Boku and Tsukasa Koyama

    Article first published online : 12 MAR 2012, DOI: 10.1111/j.1601-5215.2012.00652.x

  16. Parkinson's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 13 OCT 2006, DOI: 10.1002/9780470041000.cedt084

  17. Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 8, August 2006, Pages: 933–944, Dr Albert J. Azzaro, Dr Chad M. VanDenBerg, Dr Lawrence F. Blob, Ms Eva M. Kemper, Dr Melvin Sharoky, Dr Dan A. Oren and Dr Bryan J. Campbell

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270006289852

  18. You have free access to this content
    Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

    British Journal of Pharmacology

    Volume 132, Issue 2, January 2001, Pages: 500–506, Moussa B H Youdim, Aviva Gross and John P M Finberg

    Article first published online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703826

  19. You have free access to this content
    Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man

    British Journal of Clinical Pharmacology

    Volume 45, Issue 6, June 1998, Pages: 551–558, P. Bitsios, R. W. Langley, S Tavernor, K. Pyykkö, M. Scheinin, E. Szabadi and C. M. Bradshaw

    Article first published online : 4 JAN 2002, DOI: 10.1046/j.1365-2125.1998.00729.x

  20. Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs

    Veterinary Anaesthesia and Analgesia

    Volume 31, Issue 2, April 2004, Pages: 129–137, John R Dodam, Leah A Cohn, Harris E Durham and Balazs Szladovits

    Article first published online : 29 MAR 2004, DOI: 10.1111/j.1467-2987.2004.00164.x